🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

197 results for “Keytruda” Clear

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    High risk resected melanoma.

    phase 3 small molecule active

    1 trial

  2. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ADSTILADRIN, GEMCITABINE , DOCETAXEL

    Ferring Pharmaceuticals

    High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours

    phase 3 small molecule active

    1 trial

  3. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion

    Disc Medicine

    Patients with advanced, metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.

    phase 3 small molecule active

    1 trial

  4. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 734506

    Wuhan Createrna Science and Technology Co., Ltd

    Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.

    phase 3 small molecule active

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Boehringer Ingelheim

    non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, AB122 (Zimberelimab)

    Arcus Biosciences

    Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer

    phase 3 small molecule active

    1 trial

  7. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Datopotamab deruxtecan, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  8. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ENFORTUMAB VEDOTIN

    Merck Sharp and Dohme

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  9. KEYTRUDA 25 mg/mL concentrate for solution for infusion, FYB206, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Formycon AG

    NSCLC

    phase 3 small molecule active

    1 trial

  10. KEYTRUDA 25 mg/mL concentrate for solution for infusion, GEMCITABINE , ENFORTUMAB VEDOTIN , CISPLATIN

    Merck Sharp and Dohme

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  11. KEYTRUDA 25 mg/mL concentrate for solution for infusion, IO102-IO103

    IO Biotech

    Previously untreated, unresectable, or metastatic melanoma

    phase 3 small molecule active

    1 trial

  12. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, JNJ-42756493, JNJ-42756493, JNJ-42756493, Docetaxel-ratiopharm 20mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Janssen-Cilag International N.V.

    Advanced Urothelial Cancer

    phase 3 small molecule active

    1 trial

  13. KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Epacadostat, CETUXIMAB , Epacadostat, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , FLUOROURACIL

    Incyte

    Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies

    phase 3 small molecule active

    1 trial

  14. KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMBROLIZUMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline bag, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Ficerafusp Alfa, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Ficerafusp A

    Bicara Therapeutics

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

    phase 3 small molecule active

    1 trial

  15. KEYTRUDA 25 mg/mL concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab, Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 3 small molecule active

    1 trial

  16. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Livmoniplimab, Carboplatin 10 mg/ml Intravenous Infusion, Pemetrexed medac 500 mg powder for concentrate for solution for infusion, Cisplatin 1mg/ml Injection BP, Budigalimab

    AbbVie Deutschland GmbH & Co. KG

    Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-3475A

    Merck Sharp and Dohme

    Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS ≥50%

    phase 3 small molecule active

    1 trial

  18. KEYTRUDA 25 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, PEMETREXED, INFLIXIMAB, Rilvegostomig, PEMETREXED, CISPLATIN, CARBOPLATIN

    AstraZeneca AB

    Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

    phase 3 small molecule active

    1 trial

  19. KEYTRUDA 25 mg/mL concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Disc Medicine

    Melanoma

    phase 3 small molecule active

    1 trial

  20. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Samsung Bioepis NL B.V.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Placebo to MK-1084 25 MG, MK-1084, Placebo to MK-1084 50 mg, MK-1084

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Placebo to MK-3475, CISPLATIN , GEMCITABINE

    Merck Sharp and Dohme

    Biliary Tract Carcinoma

    phase 3 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, SUNITINIB , AXITINIB

    Merck Sharp and Dohme

    Metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline Solution

    Merck Sharp and Dohme

    Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-transit metastases)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources